Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 schedule acquisition, immunogenicity, and yellow fever co-administration study
ISRCTN72821613Phase 4Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Sep 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Prevnar 13 and 17D yellow fever vaccine in pneumococcal disease and yellow fever (3 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoints: Nasopharyngeal acquisition of vaccine-type pneumococci, Pneumococcal serotype-specific IgG concentration and 1 more. Started Sep 2020; status: completed.
02
Drugs
Prevnar 1317D yellow fever vaccine
03
Conditions
pneumococcal diseaseyellow fever
Beyond the preview
Go deeper on ISRCTN72821613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72821613.